In the News

1853 News Items found
Headshot of Ruthy Gordon, who is director of Clinical Trials Nursing at MSK.
For RuthAnn (“Ruthy”) Gordon, Director of Clinical Trials Nursing, some of the best days are when the FDA approves a drug from a clinical trial that she worked on. It’s happened to her four times.
person with insomnia
Learn about how cognitive behavioral therapy for insomnia (CBT-I) helps people with cancer improve sleep.
Luis A. Diaz, MD
Memorial Sloan Kettering Cancer Center (MSK) is proud to announce Luis Alberto Diaz, Jr., MD, Head of the Division of Solid Tumor Oncology; Grayer Family Chair at MSK, has been elected to the 10th class of Giants of Cancer Care® for his contributions in translational science.
Headshot of Vik Gill, an analyst for MSK's Institutional Review Board
Vik Gill: The Uplifter
Most children face pressures growing up — including from their parents and peers. Vik Gill wrestled with circumstances “that may sound more familiar to any child of first-generation immigrants.
A man and a woman sit on a boat wearing life jackets and holding a large icicle. An iceberg sticking out of the water is behind them.
In April 2022, the FDA approved the immunotherapy drug axicabtagene ciloleucel (Yescarta®) for the treatment of diffuse large B cell lymphoma earlier in the course of disease. Retired teacher and basketball coach Joe Crimi is one of the patients who benefited from this treatment.
Memorial Sloan Kettering Cancer Center Senior Vice President, Chief Nurse Executive, and Chair of Nursing Tracy Gosselin
Memorial Sloan Kettering's new chief nurse Tracy Gosselin says she was taken by surprise when she was asked to consider MSK's top nursing job.
Ethan Zohn is pictured in a field of cannabis plants.
Dr. Diane Reidy-Lagunes discusses cannabis and cancer with MSK’s Director of Pediatric Integrated Medicine, Dr. Nirupa Raghunathan, and cancer survivor and winner of TV’s “Survivor: Africa”, Ethan Zohn.
Headshot of MSK clinical social worker Victoria Lassen
An MSK expert gives advice on how to talk to family and friends about a cancer diagnosis linked to HPV, which some people find particularly challenging.
Christopher Klebanoff
In the Lab
Investigators at MSK are developing new immunotherapy treatments that rely on engineering T cells to recognize mutated proteins that are unique to cancer.
SKI immunologist Ming Li
The new cells, which the scientists have dubbed killer innate-like T cells, differ in several notable ways from the conventional target of many immunotherapies.